Montrouge, France, March 4, 2024
DBV Technologies announces 2023 full-year financial results and business updates on March 7, 2024
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treating food allergies, announced today that the company will conduct a conference call and audio webcast on Thursday, March 7th. announced that they will be hosting a live show. 5:00 PM ET to review full year 2023 financial results and provide business updates.
Interested participants may access this call via the conference call number below and view the DBV Technologies call.
USA: 1-844-481-2866
International call: 1-412-317-1859
A live webcast of the conference call will also be available under “Events” in the Investor section of our website at https://dbv-technologies.com/investor-overview/events. A replay of the presentation will also be available on his DBV website after the event.
About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential for applications in immunotherapy. Viaskin is based on cutaneous immunotherapy (EPIT™), his DBV Technologies method of delivering biologically active compounds to the immune system through intact skin. We are dedicated to safely transforming the care of food allergy patients with this new class of non-invasive product candidates. DBV Technologies' food allergy program includes ongoing clinical trials for Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, New Jersey. Our ordinary shares are traded on Euronext Paris Segment B (ticker: DBV, ISIN code: FR0010417345) and our ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market. (ticker: DBVT). .
Investor contact information
katie matthews
katie.matthews@dbv-technologies.com
media contact
aurora claus
aurora.krause-ext@dbv-technologies.com
Viaskin and EPIT are trademarks of DBV Technologies.
attachment